A phase 1 trial of <scp>NY‐ESO</scp>‐1‐specific <scp>TCR</scp>‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma
International journal of cancer